Autopsy report · NCT01059448

Safety and Efficacy of AMG 827 in Subjects With RA

“Lack of efficacy for Brodalumab in Rheumatoid Arthritis (RA)”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 10 months before it stopped.
• 211 participants enrolled.
• Results were posted on the registry 10 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Amgen

Sponsor type

Industry

Conditions

Rheumatoid Arthritis

Interventions

AMG 827

Participants

211

Sites

44

Countries

Bulgaria, Canada, Czechia, Latvia, Mexico, Poland, United Kingdom, United States

Trials that died the same way

• Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
  “The clinical development of intravenously administered ofatumumab in RA will no longer be pursued, so this study was prematurely terminated by the Sponsor.” (59% match in meaning)
• A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab
  “This study was cancelled because of the limited efficacy demonstrated in the ContRAst phase III programme as a potential treatment for rheumatoid arthritis. GSK has decided not to progress with regulatory submissions” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.